Sarepta told RBC patient death confirmed unrelated to Elevidys
Shares of Sarepta (SRPT) are down this morning, potentially due to the latest FDA Adverse Event Reporting System update on Elevidys, which ...
Sarepta moves off lows after speaking to RBC on patient death
The stock is down 1% to $116.14 after hitting $113.38 earlier in the morning.Invest with Confidence: Follow TipRanks' Top Wall Street Analysts ...